{"id":24847,"date":"2022-06-27T06:00:17","date_gmt":"2022-06-27T05:00:17","guid":{"rendered":"https:\/\/www.curiumpharma.com\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/"},"modified":"2022-10-04T23:08:45","modified_gmt":"2022-10-04T22:08:45","slug":"submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency","status":"publish","type":"post","link":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/","title":{"rendered":"Curium Announces The Submission Of Its Marketing Authorization Application For  [<sup>18<\/sup>F]-DCFPyL To The European Medicines Agency"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":65,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[],"class_list":["post-24847","post","type-post","status-publish","format-standard","hentry","category-comunicados-de-prensa"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency - Curium Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency - Curium Pharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/\" \/>\n<meta property=\"og:site_name\" content=\"Curium Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T05:00:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-04T22:08:45+00:00\" \/>\n<meta name=\"author\" content=\"Lauren Haynes\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lauren Haynes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/\"},\"author\":{\"name\":\"Lauren Haynes\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/9dfd1bf1b3e0c90cb6cc5575b80603ba\"},\"headline\":\"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency\",\"datePublished\":\"2022-06-27T05:00:17+00:00\",\"dateModified\":\"2022-10-04T22:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/\"},\"wordCount\":17,\"articleSection\":[\"Comunicados de prensa\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/\",\"name\":\"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency - Curium Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\"},\"datePublished\":\"2022-06-27T05:00:17+00:00\",\"dateModified\":\"2022-10-04T22:08:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/9dfd1bf1b3e0c90cb6cc5575b80603ba\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2022\\\/06\\\/27\\\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/\",\"name\":\"Curium Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curiumpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/9dfd1bf1b3e0c90cb6cc5575b80603ba\",\"name\":\"Lauren Haynes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g\",\"caption\":\"Lauren Haynes\"},\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/author\\\/lauren-haynes03gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency - Curium Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/","og_locale":"es_ES","og_type":"article","og_title":"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency - Curium Pharma","og_url":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/","og_site_name":"Curium Pharma","article_published_time":"2022-06-27T05:00:17+00:00","article_modified_time":"2022-10-04T22:08:45+00:00","author":"Lauren Haynes","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Lauren Haynes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/#article","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/"},"author":{"name":"Lauren Haynes","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/9dfd1bf1b3e0c90cb6cc5575b80603ba"},"headline":"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency","datePublished":"2022-06-27T05:00:17+00:00","dateModified":"2022-10-04T22:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/"},"wordCount":17,"articleSection":["Comunicados de prensa"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/","url":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/","name":"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency - Curium Pharma","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/#website"},"datePublished":"2022-06-27T05:00:17+00:00","dateModified":"2022-10-04T22:08:45+00:00","author":{"@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/9dfd1bf1b3e0c90cb6cc5575b80603ba"},"breadcrumb":{"@id":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.curiumpharma.com\/es\/2022\/06\/27\/submission-marketing-authorization-application-for-18f-dcfpyl-to-european-medicines-agency\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curiumpharma.com\/es\/"},{"@type":"ListItem","position":2,"name":"Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency"}]},{"@type":"WebSite","@id":"https:\/\/www.curiumpharma.com\/#website","url":"https:\/\/www.curiumpharma.com\/","name":"Curium Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curiumpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/9dfd1bf1b3e0c90cb6cc5575b80603ba","name":"Lauren Haynes","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g","caption":"Lauren Haynes"},"url":"https:\/\/www.curiumpharma.com\/es\/author\/lauren-haynes03gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/posts\/24847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/comments?post=24847"}],"version-history":[{"count":0,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/posts\/24847\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/media?parent=24847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/categories?post=24847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/tags?post=24847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}